Modalis Therapeutics Corporation
株式会社モダリス
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4883
FY2025 (Dec 2025) · J-GAAP · consolidated Source: filing S100XSHO
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Dec 2025) runs Jan 1, 2025 – Dec 31, 2025.
| Gross margin | —Not in the filing: revenue, gross profit / cost of sales |
|---|---|
| Operating margin | —Not in the filing: revenue |
| Net margin | —Not in the filing: revenue |
| Return on equity | -68.5%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | -64.7% |
| Revenue growth (YoY) | —Not in the filing: revenue |
| EPS (basic) | −¥27.86 |
| EPS growth (YoY) | —Base is zero or negative |
| Current ratio | 21.46x |
| Equity ratio | 93.0% |
| Book value / share | ¥31.80 |
| Free cash flow | −¥2.1B |